Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 32, Issue 9, 2014, Pages 905-911

  Douer, Dan ^a   Aldoss, Ibrahim ^b   Lunning, Matthew A ^a   Burke, Patrick W ^a   Ramezani, Laleh ^b   Mark, Lisa ^b   Vrona, Janice ^b   Park, Jae H ^a   Tallman, Martin S ^a   Avramis, Vassilios I ^c   Pullarkat, Vinod ^b   Mohrbacher, Ann M ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; FOLINIC ACID; IMATINIB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; STEROID; TENIPOSIDE; TIOGUANINE; VINCRISTINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; MACROGOL DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; STEROID THERAPY; THERAPY DELAY; TREATMENT DURATION; YOUNG ADULT; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; FEASIBILITY STUDY; INDUCTION CHEMOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; SEPSIS; TOXIC HEPATITIS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG-INDUCED LIVER INJURY; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERBILIRUBINEMIA; INDUCTION CHEMOTHERAPY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUTROPENIA; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SEPSIS; TREATMENT OUTCOME;

EID: 84899656097     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.2708     Document Type: Article

References (48)

1. Douer D: Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Best Practice Res Clin Haematol 21:647-658, 2008
2. Rowe JM, Buck G, Burnett AK, et al: Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial - MRC UKALL XII/ECOG E2993. Blood 106:3760-3767, 2005 (Pubitemid 41739010)
3. Goldstone AH, Richards SM, Lazarus HM, et al: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111:1827-1833, 2008 (Pubitemid 351451489)
4. Linker C, Damon L, Ries C, et al: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 20:2464-2471, 2002 (Pubitemid 34525731)
5. Thomas X, Boiron JM, Huguet F, et al: Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. J Clin Oncol 22:4075-4086, 2004 (Pubitemid 41185176)
6. Kantarjian H, Thomas D, O'Brien S, et al: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101:2788-2801, 2004 (Pubitemid 39603187)
7. Hoelzer D, Thiel E, Löffler H, et al: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 71:123-131, 1988 (Pubitemid 18050401)
8. Larson RA, Dodge RK, Burns CP, et al: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 85:2025-2037, 1995
9. Stock W, Johnson JL, Stone RM, et al: Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B study 19802. Cancer 119:90-98, 2013
10. Lamanna N, Heffner LT, Kalaycio M, et al: Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter. Cancer 119:1186-1194, 2013
11. Pulte D, Gondos A, Brenner H: Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 113:1408-1411, 2009
12. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178, 2006 (Pubitemid 43076714)
13. Stock W, La M, Sanford B, et al: What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 112:1646-1654, 2008
14. Nachman JB, Sather HN, Sensel MG, et al: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338:1663-1671, 1998 (Pubitemid 28267911)
15. Boissel N, Auclerc MF, Lhéritier V, et al: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21:774-780, 2003 (Pubitemid 46606434)
16. de Bont JM, Holt B, Dekker AW, et al: Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18: 2032-2035, 2004 (Pubitemid 40028431)
17. Hallböök H, Gustafsson G, Smedmyr B, et al: Treatment outcome in young adults and children > 10 years of age with acute lymphoblastic leukemia in Sweden: A comparison between a pediatric protocol and an adult protocol. Cancer 107:1551-1561, 2006 (Pubitemid 44546916)
18. Ramanujachar R, Richards S, Hann I, et al: Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 48:254-261, 2007 (Pubitemid 46238513)
19. Ribera JM, Oriol A, Sanz MA, et al: Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 26:1843-1849, 2008
20. Huguet F, Leguay T, Raffoux E, et al: Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study. J Clin Oncol 27:911-918, 2009
21. Goekbuget N, Beck J, Brueggemann M, et al: PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): Significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) study 07/2003. Blood 116, 2010 (abstr 494)
22. DeAngelo DJ, Dahlberg S, Silverman LB, et al: A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood 110, 2007 (abstr 587)
23. Rytting M, Kantarjian H, Thomas D, et al: Adolescent and young adult patients treated with modified augmented Berlin-Frankfurt-Muenster therapy. Blood 116, 2010 (abstr 3250)
24. Wood WA, Lee SJ: Malignant hematologic diseases in adolescents and young adults. Blood 117:5803-5815, 2011
25. Kurtzberg J, Yousem D, Beauchamp, N: Asparaginase, in Kufe DW, Pollock RE, Weichselbaum RR, et al (eds): Holland-Frei Cancer Medicine (ed 6). Hamilton, Ontario, BC Decker, 2003, pp 823-830
26. Sallan SE, Hitchcock-Bryan S, Gelber R, et al: Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 43:5601-5607, 1983 (Pubitemid 14230187)
27. Silverman LB, Gelber RD, Dalton VK, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211-1218, 2001 (Pubitemid 32183741)
28. Pession A, Valsecchi MG, Masera G, et al: Long-term results of a randomized trial on extended use of high-dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 23:7161-7167, 2005
29. Seibel NL, Steinherz PG, Sather HN, et al: Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 111:2548-2555, 2008
30. Moghrabi A, Levy DE, Asselin B, et al: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109:896-904, 2007 (Pubitemid 46220632)
31. Stock W, Douer D, DeAngelo DJ, et al: Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: Recommendations of an expert panel. Leuk Lymphoma 52:2237-2253, 2011
32. Tubergen DG, Bleyer A: The leukemias, in Behrman RE, Kliegman RM, Jenson HB (eds): Nelson's Textbook of Pediatrics (ed 17). Philadelphia, PA, Saunders, 2004, pp 1694-1698
33. Douer D, Yampolsky H, Cohen LJ, et al: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 109:2744-2750, 2007 (Pubitemid 46482066)
34. Zeidan A, Wang ES, Wetzler M: Pegasparaginase: Where do we stand? Expert Opin Biol Ther 9:111-119, 2009
35. Capizzi RL, Holcenberg JS: Asparaginase, in Holland JF, Frei E, Bast RC Jr, et al (eds): Cancer Medicine (ed 3). Philadelphia, PA, Lea & Febiger, 1993, pp 796-805
36. Avramis VI, Sencer S, Periclou AP, et al: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 99:1986-1994, 2002 (Pubitemid 34525479)
37. Veal GJ, Hartford CM, Stewart CF: Clinical pharmacology in the adolescent oncology patient. J Clin Oncol 28:4790-4799, 2010
38. Dinndorf PA, Gootenberg J, Cohen MH, et al: FDA drug approval summary: Pegaspargase (Oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 12:991-998, 2007 (Pubitemid 47359142)
39. Aguayo A, Cortes J, Thomas D, et al: Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 86:1203-1209, 1999 (Pubitemid 29447003)
40. Faderl S, Thomas DA, O'Brien S, et al: Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk 11:54-59, 2011
41. Rytting M, Earl M, Douer D, et al: Toxicities in adults with acute lymphoblastic leukemia (ALL) treated with regimens using pegasparaginase. Blood 112, 2008 (abstr 1924)
42. Wetzler M, Sanford BL, Kurtzberg J, et al: Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B study 9511. Blood 109:4164-4167, 2007 (Pubitemid 46743378)
43. Bruggemann M, Raff T, Flohr T, et al: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107:1116-1123, 2006 (Pubitemid 43156313)
44. Larsen EC, Salzer WL, Devidas M, et al: Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate (C-MTX) plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. J Clin Oncol 29:6s, 2011 (abstr 3)
45. Grace RF, Dahlberg SE, Neuberg D, et al: The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 152:452-459, 2011
46. Larson RA, Fretzin MH, Dodge RK, et al: Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 12:660-665, 1998 (Pubitemid 28220817)
47. Larson RA: Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am 14:1367-1379, 2000
48. Thomas DA, O'Brien S, Faderl S, et al: Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28:3880-3889, 2010